Impact Factor
4.08
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.03
2,273 total citations
h5-index
36
h5 depth signal
Cited share
89.6%
423 of 472
Total citations
2,273
Citation footprint
Metric signal
5.33
External metric anchor
Self-citation
1.6%
36 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
744
Japan
82
United Kingdom
79
Canada
70
Germany
58
Citing Fields of Research
Oncology
340
Immunology
302
Cancer & Development
172
Breast Cancer
140
Cancer, Autophagy & Apoptosis
119
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,025
Articles tracked across the journal lifetime
Indexed publication set
472
423 cited publications
Last 12 months
226
18.8 publications/month
Open access share
99.6%
225 OA publications in the last year
Leading citing country
United States
744 citing publications
Leading citing field
Oncology
340 citing publications
Latest tracked publication
19 December 2026
10 recent records available
Coverage & Indexing History
v1n1, Oct. 2021-
v1n1, Oct. 2021-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Oncology
Lung Cancer
Breast Cancer
Cancer & Development
Liver & Colon Cancer
Issuing & Sponsoring Bodies
issuing body
American Association for Cancer Research
Broad Categories
Neoplasms
Immunology
Cancer, Autophagy & Apoptosis
Genetics & Genomics
Cancer & Development
DNA Damage
Lymphomas
Lung Cancer
MeSH Descriptors
Medical Oncology
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1158/2767-9764.crc-25-0455
Open DOI
CCDC6 immunostaining in conjunction with the Rad51 HRD assay may expand PARPi treatment eligibility in HGSOC patients.
HGSOC patients with BRCA1/2 mutations show HRD and PARPi sensitivity. Notably, HRD and PARPi response can occur without BRCA mutations, suggesting other factors are involved. Loss of CCDC6 function can lead to HRD and PARPi sensitivity i...
02
DOI 10.1158/2767-9764.crc-25-0485
Open DOI
microRNA expression in macrophages regulates antibody-dependent effector function and B cell lymphoma therapy
CD163 positive tumour associated macrophages (TAMs) are associated with poor response to immunochemotherapy in patients with diffuse large B cell lymphoma and comprise a significant proportion of the tumour microenvironment. Targeting th...
03
DOI 10.1158/2767-9764.crc-26-0214
Open DOI
The use of TF-Ag-α to selectively capture tumor-derived extracellular vesicles and enhance the predictive performance of extracellular vesicle PD-L1 for response to immune checkpoint inhibitors
Only a subset of non-small cell lung cancer (NSCLC) patients benefits from immune checkpoint inhibitors (ICIs). Tissue PD-L1 has limited accuracy in predicting ICI response and requires invasive biopsies, highlighting the urgent need for...
04
DOI 10.1158/2767-9764.crc-25-0834
Open DOI
Elucidating the Gene Expression Signature of Rosai-Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
Rosai-Dorfman disease (RDD) is a rare histiocytic disorder characterized by accumulation of large histiocytes in nodal and/or extranodal sites. The underlying biology of RDD and factors that distinguish it from the other histiocyte disor...
05
DOI 10.1158/2767-9764.crc-26-0244
Open DOI
Androgen-mediated T cell suppression drives sex bias in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) exhibits a strong sex bias. However, the mechanisms underlying this disparity remain unclear. Using the Four Core Genotypes (FCG) mouse model to uncouple gonadal sex from sex chromosome compl...
06
DOI 10.1158/2767-9764.crc-26-0274
Open DOI
Nicotinic acid restriction potentiates NAMPT inhibition in acute myeloid leukemia xenograft models.
NAMPT, a key enzyme in NAD biosynthesis, is a potential therapeutic target in cancer. Acute myeloid leukemia (AML) is among cancer types exhibiting high NAMPT dependence, and elevated NAMPT activity is implicated in venetoclax resistance...
07
DOI 10.1158/2767-9764.crc-26-0518
Open DOI
Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure
Purpose: Limited central nervous system (CNS) bioavailability and pharmacodynamics are obstacles to effective systemic therapies for glioblastoma (GBM). One strategy to overcome these challenges is drug combinations enhancing CNS penetra...
08
DOI 10.1158/2767-9764.crc-26-0421
Open DOI
ERX 208 induces endoplasmic reticulum stress and suppresses DNA damage repair to enhance chemotherapy sensitivity
Ovarian cancer (OCa) remains the most lethal gynecologic malignancy, driven in part by intrinsic and acquired therapeutic resistance to DNA damaging chemotherapies. We previously identified that ERX-208 targets the protein encoded by Lys...
09
DOI 10.1158/2767-9764.crc-26-0343
Open DOI
HIV and Antiretroviral Therapy Influence Tumor Microenvironment Architecture, Subclonal Evolution, and Immune Evasion Strategies in Diffuse Large B-Cell Lymphoma
The tumor immune microenvironment (TIME) and tumor heterogeneity shape prognosis and therapeutic response in Diffuse Large B-cell Lymphoma (DLBCL), but HIV-associated (HIV+) DLBCL remains poorly understood. To characterize the TIME and t...
10
DOI 10.1158/2767-9764.crc-26-0388
Open DOI
Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Despite recent adoption of perioperative therapy for high-risk melanoma, its overall survival (OS) benefit remains unclear, highlighting the need for biomarkers to identify patients likely to benefit from treatment. Detection of circulat...